Upadacitinib NEW

Description:

Upadacitinib is an oral Janus kinase (JAK) inhibitor primarily used to treat autoimmune diseases. It was initially approved for the treatment of moderate to severe active rheumatoid arthritis in patients who have had an inadequate response to other therapies.

Main Uses:

Rheumatoid Arthritis: Upadacitinib helps reduce joint pain and swelling, improving overall function.

Psoriatic Arthritis: It is also used to treat psoriatic arthritis, relieving symptoms associated with the condition.

Atopic Dermatitis: The drug is indicated for moderate to severe atopic dermatitis, alleviating itching and skin inflammation.

Crohn's Disease: Research is ongoing regarding its use in other inflammatory bowel diseases, such as Crohn's disease.

Mechanism:

Upadacitinib works by inhibiting the activity of JAK enzymes, which reduces the production of cytokines and, consequently, the inflammatory response.

Precautions:

Using Upadacitinib may come with potential side effects, including an increased risk of infections and blood clots. Therefore, it is important to consult a healthcare provider before starting treatment and to have regular monitoring during therapy.